

Urgent Provision Of Current Repeat Prescribed Medicines, Appliances
And ACBS Products.


**NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF REPEAT
MEDICINES, APPLIANCES AND ACBS PRODUCTS.**


**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS.**


**IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE
MOST UP TO DATE PGD**

1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

Physician Dr George Crooks Signature 

Pharmacist Dr John McAnaw Signature 

NHS Scotland
Representative John Turner Signature 

Authorised for use on behalf of NHS Forth Valley Health Board by

Medical Director Iain Wallace Signature 

Senior Pharmacist Gail Caldwell Signature 

Clinical Governance Lead Iain Wallace Signature 

Date Approved May 15th 2012

Effective from May 15th 2012 Expires April 30th 2013

2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

3. Application

This PGD covers the urgent provision of current repeat NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists when the patient's prescriber is unavailable; the surgery is closed or if an out-of-hours system is in operation.

4. Clinical Condition

Situation	The provision from a pharmacy with an NHS contract of repeat NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for further supplies in the normal way for the clinical conditions listed in schedules 1 to 15 of this PGD.
Inclusion Criteria	<p>Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber. The requirement to interview the patient directly prior to a supply being made will be removed in the case of an announcement of a pandemic or imminent pandemic (WHO level 6).</p> <p>Medicines and/or appliances and/or ACBS products are allowed on NHS prescription.</p> <p>Surgery is closed and/or prescriber unavailable.</p> <p>Patient is registered (or temporarily) with a medical practice in Scotland.</p> <p>Patient agrees to relevant clinical information being provided to the pharmacist.</p>
Exclusion Criteria	<p>Provision is not urgent.</p> <p>Patient's medicines and/or appliances and/or ACBS products are not on repeat prescription.</p> <p>Medicines and/or appliances and/or ACBS products are not allowed on NHS prescription.</p> <p>No agreement to share relevant clinical information.</p> <p>Urgent provision for the medicines and/or appliances and/or ACBS products requested at last prescribing cycle.</p> <p>Patient's clinical condition significantly changed.</p>
Action if Excluded	Pharmacist's judgement to provide supply under existing emergency supply regulations.

Referral to Prescriber	Significant change in clinical condition.
	Any relevant reason by pharmacist.

5. Description of Treatment

Medicine	All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in the schedules to this PGD.
Legal Status	As described in the BNF or BNFC.
Dosage Form and Strength	As normally prescribed by the patient's prescriber. or Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.
Dose	As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC.
Exceptions	As listed in the Annexes to this PGD.
Duration of Supply	One prescribing cycle i.e. quantity and duration normally prescribed to the patient or up to one months supply if not known.
Patient Information	Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet. Provision of any other relevant information as judged by the pharmacist operating under this PGD.
Documentation	The pharmacist will complete a CP(US) in accordance with the requirements contained in the guidance to this PGD.
Supply	The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging.
Follow-up	Ensure that the patient's prescriber is notified and that all records are complete and CP(US) is forwarded to NHS NSS.
Adverse reactions	As described in BNF or BNFC.
Patient Charges	Normal charge equivalent to that applied to an NHS prescribed item and current NHS exemptions are applicable.

Record/Audit Trail

The CP(US) should be forwarded to NHS NSS for onward processing.

A record of the transaction i.e. a fax or photocopy of the CP(US) should be forwarded to the patient's Prescriber as soon as possible.

A record of the transaction should be entered in the patient's Prescription Medication Record.

6. Characteristic of Staff

**Qualifications
Required**

Pharmacist whose name is currently on the practising section of the pharmaceutical register held by the General Pharmaceutical Council.

SCHEDULE 1

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Gastro-Intestinal System
Section 1**

Part A: All medicines except those contained in Part B of this Schedule listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Abdominal colic/distension	Excessive respiratory secretions	Irritable bowel syndrome
Anal fissures	Faecal incontinence	Management of colostomy and ileostomy patients
Autoimmune hepatitis	Fistulas	Primary biliary cirrhosis
Bowel colic	Food allergy	Proctitis
Conditions requiring gastric acid reduction	Gastritis	Proctosigmoiditis
Constipation	Gastro-oesophageal reflux disease	Pruritus
Crohn's disease	Gastroprotection	Reduced/Absent exocrine secretion
Cystic fibrosis	Gustatory sweating	Reflux oesophagitis
Diarrhoea	Haemorrhoids	Short bowel syndrome
Dissolution of gall stones	Hepatic encephalopathy	Smooth muscle spasm
Diverticular disease	Hypersecretory conditions	Ulcerative colitis
Dysmenorrhoea	Infant colic	Ulceration including duodenal; gastric; stomal; stress; NSAID associated
Dyspepsia	Inflammatory bowel disease	Wind pain

Part B: The following medicines listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
1.2	All injections	Acute use only
1.3	All ¹	Diagnostic use only
1.3.1	All injections	Acute use only
1.3.5	All injections and infusions	Acute use only
1.5.3	All injections and infusions	Specialist use only
1.6.5	All	Acute use only
1.7.3	All	Acute use only

¹ All H.pylori tests are excluded, please refer to each individual sub section for all other exclusions.

SCHEDULE 2

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Cardiovascular System
Section 2**

Part A: All medicines except those contained in Part B of this Schedule listed in Cardiovascular System, section 2 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acute coronary syndrome	Hypercholesterolaemia	Oedema
Angina	Hyperlipidaemias	Peripheral vascular disease
Anxiety	Hypertension	Phaeochromocytoma
Arrhythmias	Hyperthyroidism	Portal hypertension
Ascites	Hypertriglyceridaemia	Prevention of MI and stroke
Cerebrovascular disease	Hypertrophic cardiomyopathy	Primary hyperaldosteronism
Coronary artery disease	Intermittent claudication	Prophylaxis of embolisation
Coronary heart disease	Left ventricular dysfunction	Pulmonary hypertension
Diabetic nephropathy	Menopausal flushing	Raynaud's syndrome
Dyslipidaemia	Menorrhagia	Renal complications of diabetes mellitus
Essential tremor	Migraine prophylaxis	Sitosterolaemia
Fibrinolysis	Myocardial infarction	Thromboembolic disease
Heart failure	Nephrotic syndrome	Thyrotoxicosis
Hereditary angioedema	Occlusive arterial disease	Transient ischaemic attack

Part B: The following medicines listed in Cardiovascular System, section 2 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
2.1.1	All injections	Acute use only
2.1.2	All	Acute use only
2.2.2	All injections	Acute use only
2.2.5	All	Acute use only
2.3.2	All injections and infusions Mexiletine Amiodarone hydrochloride sterile concentrate	Acute use only
2.4	All injections	Acute use only
2.5.1	All injections and infusions Ambrisentan Bosentan Iloprost Sildenafil Tadalafil	Specialist use only Acute use only Specialist use only
2.5.3	All	Acute use only
2.5.4	All injections Phenoxybenzamine hydrochloride Metirosine	Acute use only
2.6.1	All injections	Acute use only
2.6.2	All injections Nimodipine	Acute use only
2.7 + all subsections	All	Acute use only
2.8.1	Heparin Danaparoid Bivalirudin Lepirudin Heparin flushes Epoprostenol Fondaparinux sodium	Specialist use only
2.8.2	Apixaban	Acute Use Only
2.8.3	All	Acute use only
2.9	All injections and infusions	Specialist use only
2.10.2	All	Acute use only
2.11	All injections All blood-related products	Acute use only Specialist use only
2.13	All	Acute use only

SCHEDULE 3

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Respiratory System
Section 3**

Part A: All medicines except those contained in Part B of this Schedule listed in Respiratory System, section 3 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic disorders	Cough	Reduction of sputum viscosity
Anaphylactic reactions	Cystic fibrosis	Reversible airways obstruction
Asthma	Hypoxaemia	Rhinitis
Bronchial secretion expulsion	Nasal congestion	Urticaria
Chronic obstructive pulmonary disease	Pruritus	

Part B: The following medicines listed in Respiratory System, section 3 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
3.1.1.1	All injections and infusions	Acute use only
3.1.3	All injections	Acute use only
3.4.1	All injections	Acute use only
3.4.2	All	Specialist use only
3.4.3	All except Anapen [®] , EpiPen [®] and Jext [®] injections for self administration	Acute use only
3.5 + all subsections	All	Specialist use only
3.7	Erdosteine	Acute use only
3.9.1	Codeine phosphate Methadone hydrochloride Morphine hydrochloride	Potential for abuse Controlled drug

SCHEDULE 4

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Central Nervous System
Section 4**

Part A: All medicines except those contained in Part B of this Schedule listed in Central Nervous System, section 4 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Aggressive, violent, dangerously impulsive or self-mutilating behaviour	Generalised anxiety disorder	Nocturnal enuresis
Agitation and restlessness	Headache	Obesity
Alcohol dependence	Hypersalivation	Obsessive - compulsive disorder
Alcohol withdrawal	Hypomania	Pain
Anxiety	Infantile spasms	Panic disorders
Attention deficit hyperactivity disorder	Insomnia	Parkinson's disease
Bipolar disorder	Intractable hiccup	Phobic and obsessional states
Bulimia nervosa	Labyrinthine disorders	Post-traumatic stress disorder
Cataplexy associated with narcolepsy	Mania	Psychomotor agitation
Childhood autism	Meniere's disease	Pyrexia
Choreas	Menopausal flushing	Restless legs syndrome
Dementia	Migraine	Schizophrenia and other psychoses
Depression	Motion sickness	Sedation
Deviant antisocial sexual behaviour	Motor neurone disease	Seizures
Drug-induced extra-pyramidal symptoms	Motor tics	Sleep disorders
Dysmenorrhoea	Movement disorders	Social anxiety disorder
Dyspepsia & GORD	Myoclonus	Status epilepticus
Epilepsy	Narcolepsy	Tinnitus
Essential tremor	Nausea and vomiting	Tourette syndrome
Excitement	Neuropathic pain	Vertigo
Febrile convulsions	Nicotine dependance	Vestibular disorders

Part B: The following medicines listed in Central Nervous System, section 4 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
4.1.1	Temazepam Sodium oxybate Melatonin ²	Controlled drug Specialist use only Acute use only ²
4.1.2	All injections Meprobamate	Acute use only Controlled drug
4.1.3	All	Controlled drug
4.2.1	All injections Clozapine ³	Acute use only Registration required ³
4.4	Dexamfetamine Methylphenidate	Controlled drug
4.5.2	Phentermine Diethylpropion	Controlled drug
4.6	All injections Aprepitant Nabilone	Acute use only Controlled drug
4.7.1	All infusions	Acute use only
4.7.2	All injections Buprenorphine Diamorphine hydrochloride Dipipanone hydrochloride Fentanyl Hydromorphone hydrochloride Methadone hydrochloride Morphine salts ⁴ Oxycodone hydrochloride Oxycodone hydrochloride with naloxone Pentazocine Pethidine hydrochloride Tapentadol	Acute use only Controlled drug
4.7.4.2	Methysergide	Specialist use only
4.8.1	All injections and infusions Phenobarbital Clobazam ⁵	Acute use only Controlled drug Epilepsy only ⁵
4.8.2	All injections Midazolam	Acute use only Controlled drug
4.9.3	Botulinum toxin type A and B	Specialist use only
4.9.2	All injections	Acute use only
4.10.3	All	Controlled drug / Specialist use only

² Only Circadin® can be supplied provided the patient is currently receiving this brand.

³ Clozapine can be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that patient.

⁴ All strengths are not allowed on the PGD including oramorph 10mg/5ml.

⁵ Clobazam can be supplied under the PGD for **epilepsy only and must be endorsed SLS.**

SCHEDULE 5

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Infections
Section 5**

Part A: All medicines except those contained in Part B of this Schedule listed in Infections, section 5 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Fungal infection	Rheumatic fever
Bacterial infection	Leprosy	Tuberculosis treatment and chemoprophylaxis
Dermatitis herpetiformis	Lyme arthritis	Viral infection

Part B: The following medicines listed in Infections, section 5 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
5.1 + all subsections	All injections and infusions Rifaximin	Acute use only
5.2 + all subsections	All injections and infusions	Acute use only
5.3.1	All	Specialist use only
5.3.2 + all subsections	All infusions	Specialist use only
5.3.3 + all subsections	All	Specialist use only
5.3.4	All ⁶	Acute use only ⁶
5.3.5	All	Specialist use only
5.4 + all subsections	All	Acute use only
5.5 + all subsections	All	Acute use only

⁶ Refer to emergency planning section for distribution arrangements in the case of pandemic flu.

SCHEDULE 6

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Endocrine System
Section 6**

Part A: All medicines except those contained in Part B of this Schedule listed in Endocrine System, section 6 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acromegaly	Hereditary angioedema	Neuropathic oedema
Addison's disease	Hormone replacement therapy	Nocturia
Adrenocortical insufficiency	Hypercalcaemia	Nocturnal enuresis
Benign fibrocystic breast disease	Hyperprolactinaemia	Osteolytic lesions
Benign prostatic hyperplasia	Hyperthyroidism	Osteoporosis
Blood glucose monitoring	Hypoglycaemia	Paget's disease
Bone metastases (reduction of bone damage and pain)	Hypogonadism	Polycystic ovary syndrome
Breast pain	Hypopituitarism	Postmenopausal symptoms
Congenital adrenal hyperplasia	Hypothyroidism	Postnatal depression
Diabetes insipidus	Inappropriate secretion of antidiuretic hormone	Postponement of menstruation
Diabetes mellitus	Infertility	Premenstrual syndrome
Diffuse non-toxic goitre	Inflammatory and allergic disorders	Prolactinoma
Dysfunctional uterine bleeding	Insulin-like growth factor-I deficiency	Recurrent miscarriage
Dysmenorrhoea	Juvenile myxoedema	Thyroid carcinoma
Endometriosis	Male hypersexuality and sexual deviation	Urinalysis
Galactorrhoea	Menopausal symptoms	von Willebrand's disease
Haemophilia	Menorrhagia	
Hashimoto's thyroiditis	Menstrual disorders	

Part B: The following medicines listed in Endocrine System, section 6 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
6.1.6	Anhydrous glucose	Acute use only
6.2.1	All injections	Acute use only
6.2.2	Iodine and iodide	Acute use only
6.3.2	All injections	Acute use only
6.4.1.2	All injections	Specialist use only
6.4.2	Testosterone and esters Mesterolone	Controlled drug
6.4.3	All	Controlled drug
6.5.1	All	Specialist use only
6.5.2	All injections	Acute use only
6.6.2	All injections and infusions	Specialist use only
6.7.2	All injections	Specialist use only
6.7.3	All	Specialist use only

SCHEDULE 7

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

**BNF/BNFC Class of Medicine Obstetrics, Gynaecology and Urinary Tract Disorders
Section 7**

Part A: All medicines except those contained in Part B of this Schedule listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Benign prostatic hyperplasia	Hormone replacement therapy	Urinary retention
Bladder spasms	Menstrual disorders	Urinary urgency
Contraception	Neurogenic bladder instability	Urological pain
Dysuria	Nocturnal enuresis	Urolithiasis
Enuresis	Urinary frequency	Vaginal & vulval infections
Erectile dysfunction	Urinary incontinence	Vaginal atrophy

Part B: The following medicines listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
7.1 + all subsections	All	Specialist use only
7.3.2.2	Etonogestrel implant	Time period between repeats
7.3.2.3	All	Time period between repeats
7.3.4	All	Time period between repeats
7.3.5	All	Acute use only
7.4.4	All	Specialist use only

SCHEDULE 8

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

**BNF/BNFC Class of Medicine Malignant Disease and Immunosuppression
Section 8**

Part A: All medicines except those contained in Part B of this Schedule listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anovulatory infertility	Cancer	Nephrotic syndrome
Autoimmune conditions	Graft-versus-host disease	Organ transplantation
Bone-marrow transplantation	Mastalgia	

Part B: The following medicines listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
8.1 + all subsections	All	Specialist use only
8.2.1	All injections and infusions	Specialist use only
8.2.2	All injections and infusions ⁷	Specialist use only ⁷
8.2.3	All	Specialist use only
8.2.4	All	Specialist use only
8.3.4.1	Fulvestrant	Specialist use only
8.3.4.2	Buserelin injection Goserelin Histrelin Leuprorelin acetate Triptorelin Abiraterone Acetate ⁸ Degarelix	Specialist use only
8.3.4.3	All	Specialist use only

⁷ Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

⁸ Abiraterone acetate can be supplied under the PGD if the patient is within the required monitoring period.

SCHEDULE 9

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Nutrition and Blood
Section 9**

Part A: All medicines except those contained in Part B of this Schedule listed in Nutrition and Blood, section 9 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anaemias	Leber's optic atrophy	Scleroderma
Autoimmune hepatitis	Metabolic disorders	Selenium deficiency
Calcium deficiency	Neuropathy	Sickle-cell disease
Chronic acidotic states	Oral nutrition	Sodium depletion
Cystinuria	Peyronie's disease	Thrombocythaemia
Fluid and electrolyte loss	Potassium depletion	Tobacco amblyopia
Hypercalcaemia	Premenstrual syndrome	Vitamin deficiency states
Hyperparathyroidism	Prevention of methotrexate induced side effects	Wilson's disease
Hyperphosphataemia	Prevention of neural tube defects	Zinc deficiency
Hypophosphataemia	Prophylaxis in chronic haemolytic states	
Iron overload	Prophylaxis of dental caries	

Part B: The following medicines listed in Nutrition and Blood, section 9 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
9.1.1.2	All	Specialist use only
9.1.2	Folic acid injection	Acute use only
9.1.3	Antilymphocyte immunoglobulin Oxymetholone Desferrioxamine mesilate Eculizumab	Specialist use only Controlled drug Specialist use only
9.1.4	All injections Eltrombopag	Specialist use only
9.1.6	All	Specialist use only
9.1.7	All	Specialist use only
9.2.1.1	Polystyrene sulphonate resins	Specialist use only
9.2.2.1	All EXCEPT Water for Injections	Acute use only
9.2.2.2	All	Specialist use only

Sub Section	Excluded Drugs	Rationale
9.3	All	Specialist use only
9.5.1 + all subsections	All injections and infusions	Acute use only
9.5.2.1	All infusions	Acute use only
9.5.4	All injections	Acute use only
9.5.5	All injections	Acute use only
9.6.2	All injections	Acute use only
9.6.3	All injections	Acute use only
9.6.4	All injections	Acute use only
9.6.6	All injections	Acute use only
9.8.1	Carnitine injection Agalsidase alfa and beta Imiglucerase Velaglucerase alfa Galsulfase Idursulfase Laronidase Mercaptamine Alglucosidase alfa Nitisinone Carglumic acid Sodium phenylbutyrate Betaine Miglustat	Specialist use only
9.8.2	All	Acute use only

SCHEDULE 10

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Musculoskeletal and Joint Diseases
Section 10**

Part A: All medicines except those contained in Part B of this Schedule listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Ankylosing spondylitis	Leg cramps	Polymyositis
Dermatological conditions aggravated or caused by sunlight	Menorrhagia	Postherpetic neuralgia
Diabetic neuropathy	Migraine	Prophylaxis of familial Mediterranean fever
Dysmenorrhoea	Muscle spasm	Psoriatic arthritis
Gout	Muscle spasticity	Renal stones
Hyperuricaemia	Musculoskeletal disorders	Rheumatic disease
Immunosuppression	Myasthenia gravis	Rheumatoid arthritis
Inflammation	Osteoarthritis	Soft-tissue disorders
Juvenile arthritis	Pain	Systemic and discoid lupus erythematosus

Part B: The following medicines listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
10.1.1	All injections	Acute use only
10.1.2.2	All	Specialist use only
10.1.3	All injections and infusions Leflunomide ⁹	Specialist use only Monitoring required ⁹
10.1.4	Probenecid Rasburicase	Specialist use only Acute use only
10.2.1	All injections Amifampridine Fampridine	Specialist use only
10.2.2	All injections Cannabis extract	Specialist use only Controlled drug
10.3.1	All	Acute use only
10.3.2	Capsaicin patches	Specialist use only

⁹ Leflunomide can be supplied under the PGD if the patient is within the required monitoring period.

SCHEDULE 11

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Eye
Section 11**

Part A: All medicines except those contained in Part B of this Schedule listed in Eye, section 11 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic conjunctivitis	Epilepsy	Raised intra-ocular pressure
Anterior uveitis	Glaucoma	Seasonal keratoconjunctivitis
Chronic eye infections	Inflammation	Tear deficiency
Corneal ulcers	Mydriasis	Vernal keratoconjunctivitis
Dry eye conditions	Ocular hypertension	

Part B: The following medicines listed in Eye, section 11 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
11.3.2	All	Specialist use only
11.4.1	Loteprednol etabonate Dexamethasone Intravitreal Implant	Acute use only Specialist use only
11.5	Tropicamide Phenylephrine hydrochloride	Acute use only
11.6	All injections	Specialist use only
11.7	All	Acute use only
11.8.1	Sodium chloride	Acute use only
11.8.2	Fluorescein sodium Acetylcholine chloride Apraclonidine Pegaptanib sodium Ranibizumab Verteporfin	Specialist use only

SCHEDULE 12

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Ear, Nose and Oropharynx
Section 12**

Part A: All medicines except those contained in Part B of this Schedule listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Chronic otitis media	Oral and perioral infections	Painful inflammatory conditions of the oropharynx
Dry mouth	Oral and perioral lesions	Rhinitis
Inflammatory conditions of the nose	Oral hygiene	Sjogren's syndrome
Nasal infections	Oral ulceration and inflammation	Symptomatic relief of oral pain
Nasal polyps	Otitis externa (infection or inflammation)	

Part B: The following medicines listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
12.1.1	Aluminium acetate	Acute use only
12.1.3	All	Acute use only
12.2.2	Ephedrine hydrochloride Xylometazoline hydrochloride	Acute use only
12.2.3	Mupirocin	Acute use only
12.3.1	Flurbiprofen	Acute use only

SCHEDULE 13

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Skin
Section 13**

Part A: All medicines except those contained in Part B of this Schedule listed in Skin, section 13 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Hirsutism	Scalp disorders
Actinic keratosis	Hyperhidrosis	Skin disfigurement
Bacterial and viral infections	Hyperkeratotic skin disorders	Skin disinfection and cleansing
Bruising	Ileostomy and colostomy care	Skin protection
Chilblains	Inflammatory or damaged skin disorders	Skin ulcers
Corns and calluses	Malodorous fungating tumours	Superficial basal cell carcinoma
Dermatitis	Minor wounds, minor burns and abrasions	Superficial thrombophlebitis
Dry and eczematous skin disorders	Nappy rash	Urinary rash
Fissures	Photosensitivity	Varicose ulcers
Fistulae	Pressure sores	Varicose veins
Fungal nail infections	Pruritic skin conditions	Warts and verrucas
Fungal skin infections	Psoriasis	
Herpes	Rosacea	

Part B: The following medicines listed in Skin, section 13 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
13.3	Topical local anaesthetics Topical antihistamines	Acute use only
13.5.1	Alitretinoin	Specialist use only
13.5.2	Acitretin	Specialist use only
13.5.3	All injections and infusions	Specialist use only
13.6.2	Isotretinoin	Specialist use only
13.7	Podophyllotoxin	Specialist use only
13.10.1.1	Mupirocin Neomycin sulphate Retapamulin	Acute use only
13.10.4	All	Acute use only
13.10.5	All skin tissue adhesives	Acute use only
13.12	Glycopyrronium bromide	Specialist use only

SCHEDULE 14

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine

Immunological Products and Vaccines Section 14

Part A: All medicines except those contained in Part B of this Schedule listed in Immunological Products and Vaccines, section 14 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

Part B: The following medicines listed in Immunological Products and Vaccines, section 14 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
Chapter 14	All	Specialist use only

SCHEDULE 15

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Anaesthesia
Section 15**

Part A: All medicines except those contained in Part B of this Schedule listed in Anaesthesia, section 15 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Local anaesthesia	Pain relief	Postherpetic neuralgia
-------------------	-------------	------------------------

Part B: The following medicines listed in Anaesthesia, section 15 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
15.1 + all subsections	All	Acute use only
15.2	All injections and infusions Lidocaine solution Lidocaine spray Lidocaine with phenylephrine solution	Acute use only